Skip to main content

Table 1 Basic characteristics of the 9,528 patients who underwent an initial IVF/ICSI cycle

From: Influence of endometrial thickness on treatment outcomes following in vitro fertilization/intracytoplasmic sperm injection

  Group A (≤8 mm) Group B (9–14 mm) Group C (≥15 mm) p
NO. 464 7,539 1,525  
Age (year) 30.44 ± 4.065 29.95 ± 4.367 30.07 ± 4.322 0.060
BMI (kg/m2) 21.3 ± 2.32 22.39 ± 3.07 22.33 ± 3.55 0.142
Duration of infertility (year) 3.64 ± 2.5 4.5 ± 3.62 4.6 ± 3.39 0.351
Basal FSH (IU/L) 7.76 ± 2.4 7.63 ± 2.71 7.79 ± 2.5 0.045
Gn (days) 12.09 ± 1.68 12.04 ± 1.64 12.10 ± 1.60 0.342
Gn dosage (IU) 2,163.21 ± 1,263.01 2,149.34 ± 876.44 2,156.46 ± 844.392 0.943
Type of Gn
 Recombinant FSH 83.78%(389) 86.99%(6,558) 87.60%(1,336) 0.101
 Urinary FSH 16.22%(75) 13.01%(981) 12.40%(189) 0.101
Endometrial pattern
 Triple line pattern 71.39%(331) 87.54%(6,599) 83.91%(1,279) 0.000
 No-triple line pattern 28.61%(133) 12.46%(940) 17.09%(246) 0.000
  IVF 81.03%(376) 77.99%(5,880) 76.19%(1,162) 0.096
  ICSI 18.96%(88) 22.01%(1,659) 23.81 (363) 0.096
 Long agonist protocol 100%(464) 100%(7,539) 100%(1,525) NS
 No. of transferred embryos 2 2 2 NS
Infertility diagnosis
 Tubal factor 57.11%(265) 51.29%(3867) 42.29%(645) 0.000
 Male factor 28.23%(131) 38.49%(2902) 40.06%(611) 0.000
 Endometriosis, pelvic and uterine factors 5.38%(25) 5.50%(415) 5.83%(89) 0.865
 Unexplained and others 9.26%(43) 4.70%(355) 11.80%(180) 0.000
  1. Values are the mean ± SD unless otherwise noted
  2. BMI body mass index, FSH Follicle-stimulating hormone, Gn gonadotropin treatment, IVF in vitro fertilization, ICSI intracytoplasmic sperm injection, NS no significance